Novartis: Menveo protects infants against meningococcal disease
BASEL, Switzerland An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in infants, according to results of a late-stage clinical trial released Monday.
The Swiss drug maker said results of a phase-3 trial showed that Menveo (meningococcal group A, C, W135 and Y) induced immune responses in a high percentage of babies against four strains of the bacteria. Meningococcal disease occurs suddenly and can cause serious illness and often death during the first year of life.
“In my practice, I have seen the devastating effects of meningococcal disease in infants,” study investigator Stan Block said. “Meningococcal vaccines are being developed that can provide broad protection against the disease in this vulnerable population.”